Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Trillium Therapeutics Inc (TRIL) Common Stock NPV

Sell:8.21 CAD Buy:8.57 CAD Change: 0.12 CAD (1.45%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Sell:8.21 CAD
Buy:8.57 CAD
Change: 0.12 CAD (1.45%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Sell:8.21 CAD
Buy:8.57 CAD
Change: 0.12 CAD (1.45%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Contact details

2488 Dunwin Drive
L5L 1J9
+1 (416) 5950627

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
877.74 million CAD
Shares in issue:
103.14 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • Jan Skvarka
    President, Chief Executive Officer, Director
  • James Parsons
    Chief Financial Officer
  • Rosemary Harrison
    Senior Vice President, Corporate Development and Strategy
  • Robert Uger
    Chief Scientific Officer
  • Ingmar Bruns
    Chief Medical Officer
  • Penka Petrova
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.